Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma

Nicole L. Michmerhuizen, Elizabeth Leonard, Chloe Matovina, Micah Harris, Gabrielle Herbst, Aditi Kulkarni, Jingyi Zhai, Hui Jiang, Thomas E. Carey, and J. Chad Brenner

Departments of Pharmacology (N.L.M., T.E.C., J.C.B.) and Otolaryngology—Head and Neck Surgery (N.L.M., E.L., C.M., M.H., G.H., A.K., T.E.C., J.C.B.), and Rogel Cancer Center (T.E.C., J.C.B.), University of Michigan Medical School, and Department of Biostatistics, University of Michigan School of Public Health (J.Z., H.J.), Ann Arbor, Michigan

Received November 5, 2018; accepted February 21, 2019

ABSTRACT

Head and neck squamous cell carcinoma (HNSCC) is a common and debilitating form of cancer characterized by poor patient outcomes and low survival rates. In HNSCC, genetic aberrations in phosphatidylinositol 3-kinase (PI3K) and epidermal growth factor receptor (EGFR) pathway genes are common, and small molecules targeting these pathways have shown modest effects as monotherapies in patients. Whereas emerging preclinical data support the combined use of PI3K and EGFR inhibitors in HNSCC, in-human studies have displayed limited clinical success so far. Here, we examined the responses of a large panel of patient-derived HNSCC cell lines to various combinations of PI3K and EGFR inhibitors, including EGFR agents with varying specificity and mechanistic characteristics. We confirmed the efficacy of PI3K and EGFR combination therapies, observing synergy with α isoform-selective PI3K inhibitor HS-173 and irreversible EGFR/ERBB2 dual inhibitor afatinib in most models tested. Surprisingly, however, our results demonstrated only modest improvement in response to HS-173 with reversible EGFR inhibitor gefitinib. This difference in efficacy was not explained by differences in ERBB target selectivity between afatinib and gefitinib; despite effectively disrupting ERBB2 phosphorylation, the addition of ERBB2 inhibitor CP-724714 failed to enhance the effect of HS-173 gefitinib dual therapy. Accordingly, although irreversible ERBB inhibitors showed strong synergistic activity with HS-173 in our models, none of the reversible ERBB inhibitors were synergistic in our study. Therefore, our results suggest that the ERBB inhibitor mechanism of action may be critical for enhanced synergy with PI3K inhibitors in HNSCC patients and motivate further preclinical studies for ERBB and PI3K combination therapies.

Introduction

Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common form of cancer by incidence worldwide and is often associated with either high alcohol and tobacco use or infection with high-risk human papilloma virus (HPV) (Kamangar et al., 2006) (https://seer.cancer.gov/archive/csr/1975_2013/). The disease has 5-year survival rates of less than 50% for HPV-negative tumors and around 80% for HPV-positive tumors, and we believe that overall survival for patients will be improved by advancing novel therapeutic approaches that target aberrations common to different subsets of HNSCC tumors (Giefing et al., 2016; Ludwig et al., 2016). Furthermore, the development of effective, rational combination therapies may be critical for overcoming common resistance mechanisms that emerge after targeted monotherapy. We believe this approach may have utility for both adapting clinical paradigms with adjuvant/neoadjuvant agents, as well as advancing personalized medicine approaches through the development of rational combination therapies for the most prominent molecular alterations in HNSCC.

Of the potential targetable molecular alterations common to HNSCC, the phosphoinositide-3 kinase (PI3K) pathway is disrupted through genomic amplifications or activating point mutations in >30% of tumors (Lui et al., 2013; Murugan et al., 2013; Gillison et al., 2015; Michmerhuizen et al., 2016), and the epidermal growth factor receptor (EGFR) is overexpressed in >90% of tumors (Ozanne et al., 1986; Lui et al., 2013; Gillison et al., 2015). Inhibitors to each of these pathways have already been advanced individually in HNSCC. For example,
in a recent phase 2 trial, pan-PI3K inhibitor BKM120 (buparlisib) with paclitaxel improved survival compared with paclitaxel and placebo in recurrent and metastatic HNSCC patients (Soulie`res et al., 2017), and EGFR antibody cetuximab is currently in clinical use after demonstrating improved outcomes in combination with radiotherapy or cisplatin (Bonner et al., 2006; Vermorken et al., 2008). Thus, although PI3K and EGFR targeting therapies have been used with some clinical success, response rates are still relatively low, and innate or acquired resistance mechanisms appear to be widespread (Bonner et al., 2006; Vermorken et al., 2008; Boekx et al., 2013; Rodon et al., 2014; Michmerhuizen et al., 2016; Soulie`res et al., 2017).

Preclinical data indicate that dual therapies directed against both PI3K and EGFR pathways might improve responses in HNSCC (Rebucci et al., 2011; Young et al., 2013; D’Amato et al., 2014; Lattanzio et al., 2015; Michmerhuizen et al., 2016; Anisuzzaman et al., 2017; Silva-Oliveira et al., 2017). Given these promising data, several clinical trials assessing the combination in HNSCC have been opened, most of which use the EGFR-targeting antibody cetuximab in combination with various inhibitors of PI3K (e.g., NCT01816984, NCT2282371, NCT02822482). Unfortunately, however, one study showed no significant improvement in patient survival with the addition of pan-PI3K inhibitor PX-866 to cetuximab (Jimeno et al., 2015). These surprising data suggested that a deeper understanding of the molecular mechanisms of action that drive response to PI3K and EGFR therapies is necessary to fully interpret the results of these trials.

Here, because of the early reported disparity between in vitro and clinical trial results, we conducted further studies characterizing the responses to various classes of PI3K and EGFR dual therapies in HNSCC. We used a panel of genetically diverse HNSCC cell lines to examine responses to combinations of PI3K and EGFR inhibitors; in doing so, we sought to assess patterns of response that might translate to future clinical trial design and/or serve as a guide for future precision medicine protocols in HNSCC.

Materials and Methods

Cell Culture. Cells were cultured in a humified incubator at 37°C with 5% (vol/vol) CO₂. UM-SCC cells (University of Michigan) and human tumor cell line Cal-33 (a kind gift from Dr. Anthony Nichols) were previously derived from HNSCC patient tumor samples and cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum, 1× penicillin/streptomycin, 1× nonessential amino acid (Brenner et al., 2010). HSC-2, HSC-4 (both from Japanese Collection of Research Bioresources through Sekisui XenoTech, Kansas City, KS), and Detroit 562 (American Type Culture Collection, Manassas, VA) cells were cultured in Eagle’s minimum essential medium with 10% fetal bovine serum, 1× penicillin/streptomycin. All cell lines were genotyped to confirm authenticity and were mycoplasma-negative.

Details of DNA copy number analysis are published elsewhere (Ludwig et al., 2018). All UM-SCC cell lines were confirmed to contain PIK3CA, as previously reported from Nimblegen V2 exome capture-based experiments (Liu et al., 2013). Cal-33, HSC-2, and HSC-4 copy number data were obtained from the publicly available canSAR database (Halling-Brown et al., 2012; Bulusu et al., 2014). EGFR mutation status or copy number was similarly assessed using data from Nimblegen V2 exome capture-based experiments (Liu et al., 2013) for UM-SCC cell lines; the canSAR database for HSC-2, HSC-4, and Cal-33 (Halling-Brown et al., 2012; Bulusu et al., 2014); and previously published work for Detroit 562 (Young et al., 2013).

Genomic DNA Purification. Cells from models with PIK3CA mutations (Cal-33, HSC-2, HSC-4, Detroit 562, UM-SCC-43, UM-SCC-19, UM-SCC-85) were harvested and washed in phosphate-buffered saline (PBS) and then frozen at –20°C. The thawed cell pellet was resuspended in 700 μl of Nuclei Lysis solution (Promega, Madison, WI) for 1 hour at 55°C. Then 200 μl of Protein Precipitation solution (Promega) was added to the sample, which was mixed and placed on ice for at least 5 minutes before being centrifuged at 13,000 rpm for 4°C for 5 minutes. The supernatant was transferred to a tube containing 600 μl of isopropanol and centrifuged at 13,000 rpm for 1 minute. After aspirating the resulting supernatant, the DNA pellet was washed in 200 μl of 70% ethanol, dried, and resuspended in 30–50 μl of nuclelease-free water.

Sanger Sequencing. Genomic DNA was amplified using polymerase chain reaction (PCR) with Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions and the primers with sequences listed in Supplemental Fig. 1. After being inserted into the pCR8 vector system or processed using the Qiagen QIAquick PCR purification kit, PCR products were submitted for Sanger sequencing at the University of Michigan DNA Sequencing Core on the 3730XL DNA Sequencer (Applied Biosystems, Foster City, CA) as described elsewhere (Birkeland et al., 2017). Sequences were aligned using the DNASTAR Lasergene software suite (DNASTAR, Inc, Madison, WI).

Chemicals. All compounds (BYL719, HS-173, BKM120, afatinib, gefitinib, erlotinib, BMS-599626, AEE788, TAK-265, CUDC-101, and duocarmab) were purchased from Selleck Chemicals (Houston, TX). Each inhibitor was initially dissolved in 100% sterile dimethylsulfoxide (DMSO) to 10 mM and then diluted in media to the indicated concentrations for studies in vitro. Table S2 gives the chemical name for each inhibitor used here.

Resazurin Cell Viability Assay. Resazurin cell viability assays were performed as described previously (Shum et al., 2008; Birkeland et al., 2016; Michmerhuizen et al., 2016). To study relative cell viability, 2000 cells/well (for all cell lines except HSC-2, for which the cell density was reduced to 1000 cells/well owing to large cell size and rapid growth rate) were seeded (in 50 μl volume) in 384-well microplates using a Biotech (Winoo, VT) Multiflo liquid-handling dispensing system. Cells adhere overnight before treatment. Inhibitors were prepared by hand from 10 mM stocks at 200 μM concentration in a 96-well plate, then diluted 10× concentration in media in a second 96-well plate using the Agilent (Santa Clara, CA) Bravo Automated Liquid Handling Platform and VWorks Automation Control Software. The intermediate plate with inhibitors in media was used to treat the cells with the desired compound concentration, again using liquid-handling robotics such that cells were treated with complete media containing 0.5% inhibitor or DMSO in a 10-point 2-fold dilution series. Each treatment was administered in quadruplicate. Cells were stained with 10 μl of 440 μM resazurin (Sigma, St. Louis, MO) dissolved in serum-free media for 12–24 hours before fluorescent signal intensity was quantitated. Quantification occurred after 72-hour treatment using the Biotek Cytation3 fluorescence plate reader at excitation and emission wavelengths of 540 and 612 nm, respectively. Data were plotted using Prism 7 and fit with concentration response curves using the log(inhibitor) versus response–variable slope model with four parameters (IC₅₀, top, bottom, and Hill slope) allowed to vary.

Annexin V Apoptosis Assay. To study annexin V presentation, 115,000 Detroit 562 cells or 100,000 UM-SCC-59 cells/well were seeded in six-well plates. After 24 hours, media were aspirated and replaced with 3 ml of fresh, complete media. One milliliter of media containing DMSO or inhibitor(s) was added to each well. Cells were cultured for 72 hours, at which time, media were collected from each well. Each well was then washed in PBS, which was also collected. Finally, cells were trypsinized and added to the suspension. Samples were then centrifuged, washed once with PBS, and counted using the Countess Automated Cell Counter (Invitrogen). One hundred thousand cells/sample were stained with annexin V fluorescein isothiocyanate (FITC) and phosphatidylidinositol using the Dead Cell Apoptosis Kit (ThermoFisher, Waltham, MA)
according to manufacturer's instructions. Five microliters of annexin V FITC and 5 μl of phosphatidylidylinositol were added to each sample. Samples were incubated at room temperature in the dark for 15 minutes and analyzed using the Bio-Rad ZE5 or MoFlo Astrios EQ Cell Sorter at the University of Michigan Flow Cytometry Core.

**Western Blotting.** Cells at 70%–80% confluency were treated with DMSO or inhibitor before harvesting and lysing in radiomunoprecipitation assay buffer (cat. no. 89900; ThermoFisher) containing 1% NP-40 and 0.1% SDS. Eight to 20 μg of each cell harvest was used, and standard Western blot protocols were followed as previously described (Birkeland et al., 2016). Primary antibodies (described in detail in Supplemental Table 1) were incubated overnight at 4°C or for at least 1 hour at room temperature, followed by a goat anti-rabbit horseradish peroxidase (cat. no. 111-035-045; Jackson ImmunoResearch, West Grove, PA) secondary antibody at room temperature for 1 hour as described elsewhere (Tillman et al., 2016). The blots were then visualized with chemiluminescence and imaged. Three hundred dots per inch or greater images were digitally retrieved from all Western blots, and representative blots are shown. ImageJ software (NIH) was used to quantify protein expression and compare treatment responses.

**Synergy Analysis.** The effects of combination treatments were analyzed with Combenefit software (Di Veroli et al., 2016) using the highest single agent model (Bliss, 1939; Berenbaum, 1981; Greco et al., 1995; Borisy et al., 2003; Mathews Griner et al., 2014). For each cell line and pair of inhibitors, the number of concentration combinations with scores >20 was counted. These counts were averaged across at least two (and as many as five) independent replications for each experiment. Experiments having more than eight concentration combinations with scores >20 were considered additive or synergistic. We compared the number of concentration combinations with scores >20 for HS-173 and afatinib (afatinib combination score), as well as HS-173 and gefitinib (gefitinib combination score). Cell lines were considered more responsive to the afatinib combination if the afatinib combination score exceeded the gefitinib combination score by eight or more.

**Statistical Analysis.** To determine whether statistically significant differences occurred with combination treatments, a two-way analysis of variance (ANOVA) was performed in R to compare the natural logarithm of the percentage of living cells after vehicle, HS-173, gefitinib or afatinib, or combination treatment. Specifically, this test was performed using type III analysis with the ANOVA function from the "car" package. The interaction between HS-173 and gefitinib or afatinib treatment indication was tested by F-test for the synergy effect of drug combination. In total, four separate tests on each cell line and pair of inhibitors, the number of concentration combinations with scores >20 was counted. These counts were averaged across at least two (and as many as five) independent replications for each experiment. Experiments having more than eight concentration combinations with scores >20 were considered additive or synergistic. We compared the number of concentration combinations with scores >20 for HS-173 and afatinib (afatinib combination score), as well as HS-173 and gefitinib (gefitinib combination score). Cell lines were considered more responsive to the afatinib combination if the afatinib combination score exceeded the gefitinib combination score by eight or more.

**Results**

**Subsets of HNSCCs Respond to PI3K + EGFR Inhibitor Combination Therapies.** To first probe the co-dependence of HNSCC cell lines to PI3K and EGFR pathway inhibitors, we compared the response of a small panel of models to the PI3Kα inhibitor HS-173 (Lee et al., 2013; Rumman et al., 2016) and irreversible pandual-EGFR/ERBB2 inhibitor afatinib (Li et al., 2008) as monotherapies and in combination. We selected HS-173 as the PI3K inhibitor as it was the most effective and isoform-selective small molecule in our panel of cell lines. Afatinib was used as the ERBB inhibitor; this drug was approved by the Food and Drug Administration in 2016 as a first-line treatment of patients with non-small-cell lung cancer whose tumors harbored mutations in EGFR. It has also displayed efficacy in HNSCC (NCT00514943) and is being evaluated in ongoing studies using various paradigms (NCT01824823, NCT01415674, NCT01427478, NCT02979977). PI3K and ERBB inhibitor combination experiments were performed in four models with PIK3CA mutations (HSC-2, HSC-4, Detroit 562, and Cal-33; Supplemental Fig. 1) and one with high-level PIK3CA amplification (UM-SCC-59, five wild-type copies) using a resazurin cell viability assay after 72-hour drug treatment and then validated by annexin V apoptosis assay (below). Our studies showed variable responses by cell line.

HSC-2, HSC-4, and Detroit 562 display a hotspot PIK3CA mutation (indicating activation of and likely dependence on the PI3K signaling pathway) but have limited responses to HS-173 and other PI3K inhibitors as monotherapies, with IC50 close to or exceeding 1 μM. In these three cell lines, we observed that the addition of afatinib to HS-173 resulted in dose-dependent improvements in the efficacy of PI3K inhibition (Fig. 1, A–C). These results represented drug synergy using the highest single agent model. This effect was also observed when pan-PI3K inhibitor BK2M120 and another PI3Kα inhibitor, BYL719, were titrated with afatinib (Supplemental Fig. 2, A and B) but not when p110δ inhibitor TGX-221 was tested in combination (Supplemental Fig. 2C), suggesting that the synergistic dose combination response specifically requires inhibition of PI3Kα. Similarly, titrating afatinib into constant concentrations of HS-173 or BK2M120 resulted in synergistic responses in combination-responsive PIK3CA mutant cell lines HSC-4 and Detroit 562 (Supplemental Fig. 3). In contrast, the data also demonstrated that one of the PIK3CA mutant HNSCC cell lines, Cal-33, as well as the PIK3CA-amplified cell line, UM-SCC-59, showed little combination benefit (Fig. 1, D and E), suggesting that these models depend on alternative survival pathways.

After establishing that subsets of HNSCCs responded synergistically to HS-173 and afatinib, we examined the downstream signals in the PI3K and EGFR pathways to identify potential differences in signaling transduction pathways between two combination-responsive models (HSC-2 and Detroit 562) and one combination nonresponsive model (Cal-33). Thus, after a 6-hour treatment with vehicle (DMSO), HS-173 monotherapy, afatinib monotherapy, or HS-173 and afatinib combination therapy, we evaluated EGFR and ERBB2 phosphorylation, as well as effector signaling through protein kinase B (AKT), MAPK/ERK kinase (mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, MEK), and extracellular signal-regulated kinase (ERK) (Fig. 2). As expected, afatinib monotherapy could inhibit EGFR and ERBB2 phosphorylation. Although the degree of reduction that afatinib reduced ERBB2 phosphorylation in lysates from treated Detroit 562 cells was fairly minimal, more robust effects on ERBB2 phosphorylation are visible after shorter treatment times (likely due to transient effects on receptor phosphorylation; see Fig. 3C below). Downstream of these effects on EGFR and ERBB2 signaling, ERK and MEK phosphorylation are similarly decreased in nonresponsive Cal-33 and responsive HSC-2 cell lines. Detroit 562 cells display minimal changes in MEK phosphorylation after shorter treatment at this dose and time point, yet ERK phosphorylation is reduced somewhat. AKT phosphorylation, used as a readout of primarily PI3K but also EGFR pathway activity, was reduced in HS-173 monotherapy–treated samples in each cell line. In the responsive HSC-2 cell line, a further reduction in AKT phosphorylation was evidenced...
with the addition of afatinib to HS-173. Thus, in nonresponsive and responsive models, inhibition of PI3K's downstream signaling through AKT and inhibition of ERBB signaling both at the receptor level and downstream through MEK and ERK was achieved (Fig. 2), indicating that the combination effect was not limited to models with reductions in effector signaling.

Responses to PI3K + EGFR Inhibition Vary Based on Inhibitor Type. We further investigated the role of ERBB inhibition in HS-173 and afatinib combination response by testing PI3K inhibitor HS-173 in combination with reversible EGFR inhibitor gefitinib in the responsive PI3K mutant HNSCC models Detroit 562 and HSC-2. Resazurin cell viability experiments performed displayed a much less marked effect with HS-173 and gefitinib compared with cotreatment with HS-173 and afatinib (Fig. 3, A and B). These effects were confirmed using an orthogonal annexin V apoptosis assay. For example, in the Detroit 562 cell line (synergistically responsive to HS-173 and afatinib), we observed higher levels of FITC-positive (apoptotic) cells after di-therapy compared with what would be expected from additive effects of HS-173 and afatinib monotherapies (adjusted $P$ value = 0.009, two-way ANOVA). Importantly, no significant change in cell death was seen in the non-synergistically responsive UM-SCC-59 model (adjusted $P$ value = 1, two-way ANOVA), and HS-173 combinations with gefitinib were ineffective in both cell lines (adjusted $P$ values = 1, two-way ANOVA) (Fig. 4). These data suggested a significant difference in the ability of gefitinib and afatinib to induce synergistic cell kill in our models.

Given this surprising observation, we expanded our original analyses on five cell lines with a larger panel of HNSCC models. Here, we selected an additional nine models with genetic characteristics of tumors most likely to receive PI3K or EGFR inhibitors in a precision medicine setting, including those with either $PIK3CA$ mutations or high-level gene amplifications (>4 copies). Consistent with our previous data (Michmerhuizen et al., 2016), the additivity between HS-173 and gefitinib was observed in only 4 of 14 (29%) of models (Fig. 5A).
Importantly, much more significant “further benefit,” which we define as including multiple synergistic dose combinations, was observed with HS-173 and afatinib combination therapy in 8 of 14 (57%) of models (Fig. 5A). Of the four models that demonstrated additivity with gefitinib, three received further benefit with afatinib. The in vitro models that failed to display robust improvements in response to HS-173 with the addition of afatinib included Cal-33 (Fig. 1D), UM-SCC-59 (Fig. 1E), UM-SCC-19, UM-SCC-43, and UM-SCC-85 (Fig. 5A). Cal-33, UM-SCC-19, UM-SCC-43, and UM-SCC-85, like some of the combination-responsive models discussed herein, display activating mutations in \( \text{PIK3CA} \) (Supplemental Fig. 1). Cal-33 and UM-SCC-85 cells were among the most sensitive to PI3K inhibitor monotherapies, whereas UM-SCC-59 (with high-level amplification of wild-type \( \text{PIK3CA} \)) is one of the most resistant. Thus, neither \( \text{PIK3CA} \) mutation nor responsiveness to PI3K inhibitor monotherapy is a good predictor of responsiveness to HS-173 and afatinib cotreatment. Likewise, at least when considered as single variables, \( \text{PIK3CA} \) copy number (Fig. 5A), \( \text{EGFR} \) copy number (Fig. 5A), and \( \text{ERBB} \) protein expression (Fig. 5B) are also poor indicators of combination response. Although mutations in \( \text{EGFR} \) are closely linked to responses to EGFR inhibitors (Lynch et al., 2004; Paez et al., 2004; Yu et al., 2013, 2015; Thress et al., 2015; Wu et al., 2016), the cell lines used here did not display such variants. Thus, neither sensitivity nor resistance to EGFR inhibitor monotherapies or combination therapies can be explained by the presence of L858R or T790M/C797S mutations, respectively. After our resazurin assay determined that the HS-173 and gefitinib combination was largely ineffective compared with HS-173 and afatinib, we tested the combination of HS-173 and afatinib in UM-SCC-110 and patient-matched fibroblasts and demonstrated the inability of combination therapy to drive cell death in normal fibroblasts (Supplemental Fig. 4).

**Fig. 2.** Signaling responses to HS-173 + afatinib in combination responsive and nonresponsive HNSCC cell lines. Western blot analysis of downstream PI3K and RAS-MEK-ERK pathway activation after 6-hour treatment with vehicle (DMSO), EGFR/ERBB2 inhibitor afatinib, PI3K\(\alpha\) inhibitor HS-173, and a combination in Cal-33, Detroit 562 and HSC-2 cell lines. HSP90 was used as a loading control. Representative images are shown.
562 were treated with vehicle (DMSO), PI3K responsive model UM-SCC-59 and combination responsive model Detroit 562 cells treated with vehicle (DMSO), PI3K inhibitor HS-173, reversible EGFR inhibitor gefitinib, and/or EGFR/ERBB2 irreversible inhibitor afatinib for 72 hours. Cell viability was measured using an annexin V apoptosis assay after cells were stained with FITC and PI. Data shown represents the mean and S.D. from two to three independent experiments. **Significance with P < 0.01 using two-way ANOVA to compare vehicle, HS-173, gefitinib, and afatinib, and combination, as described in Materials and Methods. Comparisons for HS-173 and gefitinib combinations in each cell line and for HS-173 and afatinib combination in UM-SCC-59 were performed but are not shown given the lack of significant interaction term.

Together, these data strongly suggest important differences between afatinib- and gefitinib-based combinations in our model system. Given the differences between the inhibitors, we hypothesized that the greater effectiveness with afatinib over gefitinib may be due to 1) a broader spectrum of ERBB family member inhibition and/or 2) irreversible as opposed to reversible inhibition of EGFR. To begin testing this hypothesis using combination responsive Detroit 562 cells, we performed a resazurin cell viability assay in which we compared the effects of HS-173 and gefitinib with or without ERBB2-specific inhibitor CP-724714 (Fig. 3B). This assay demonstrated that CP-724714 was unable to add to HS-173 and gefitinib in this assay, and the total effect of this tritherapy combination remained much less substantial than the effect of HS-173 and afatinib. This result suggested the possibility that ERBB2 inhibition did not account for the differences between inhibitors or that CP-724714 could not sufficiently inhibit ERBB2 signaling in our system.

Consequently, to validate that the doses of CP-724714 used here could sufficiently inhibit ERBB2 signaling, we performed Western blot analysis on lysates harvested from Detroit 562 cells after CP-724714 or afatinib treatment. At doses equivalent to or less than those used in resazurin cell viability assays, we observed that both CP-724714 and afatinib treatment resulted in robust inhibition of ERBB2 phosphorylation after 15 or 60 minutes (Fig. 3C). We also examined lysates from HSC-2 cells after 2-hour treatment with each monotherapy or ditherapy (Fig. 5C). This demonstrated decreased EGFR phosphorylation in gefitinib- and afatinib-treated samples, with a slightly greater loss of EGFR phosphorylation with afatinib than gefitinib. Phosphorylation of ERK, GAB1, and MEK, downstream of EGFR, were similar for gefitinib and afatinib treatments; in addition, cotreatment with HS-173 and gefitinib or afatinib did not reduce downstream ERBB signals beyond those levels seen with gefitinib and afatinib monotherapy treatments. Phosphorylation of PI3K pathway effector AKT was appropriately inhibited upon HS-173 treatment, but PDK1 and GSK3β phosphorylation remained unchanged. Together, these data suggest that ERBB2 inhibition alone may not explain the differences between the gefitinib and afatinib combinations and therefore warrant further evaluation of differences between reversible and irreversible ERBB inhibitor combinations.

Thus, using a resazurin cell-viability assay, we tested HS-173 in combination with three reversible ERBB inhibitors (erlotinib, BMS-599626, and CP-724714) and three irreversible ERBB-targeting agents (TAK285, CUDC-101, and dacomitinib) in HSC-2 and Detroit 562 cells. Although we observed that none of the four (0%) reversible ERBB inhibitors displayed synergistic dose combinations in either cell line, three of four (75%) and four of four (100%) irreversible ERBB-targeting drugs had synergistic dose combinations with HS-173 in Detroit 562 and HSC-2 cells, respectively (Supplemental Fig. 5; Table 1). These data add support to the hypothesis that irreversible inhibition of EGFR and/or its ERBB family members may be important for achieving the most significant growth inhibition with PI3K and ERBB inhibitor combinations.

**Discussion**

Our data are consistent with previous studies showing the benefit of PI3K- and EGFR- inhibitor combination therapies (Rebucci et al., 2011; Young et al., 2013; D’Amato et al., 2014; Lattanzio et al., 2015; Michmerhuizen et al., 2016; Anisuzzaman et al., 2017; Silva-Oliveira et al., 2017) and also extend that work by discovering that PI3K inhibitors are much more effective in combination with irreversible than reversible EGFR inhibitors in HNSCC. In prior work comparing the classes of EGFR-targeting monotherapies in this cancer type, preclinical data demonstrated that irreversible EGFR inhibitors are superior to other EGFR-targeting agents, including cetuximab (Ather et al., 2013; Silva-Oliveira et al., 2017) and reversible inhibitor gefitinib (Young et al., 2015). Similarly, previous work has shown that the addition of ERBB2-targeting antibodies pertuzumab (Erjala et al., 2006) or trastuzumab (Kondo et al., 2008) to gefitinib enhances its efficacy in HNSCC cell lines; however, our findings demonstrated that the broader specificity of irreversible inhibitors alone cannot explain these differences in sensitivity, as administering ERBB2-inhibitor CP-724714 with gefitinib and HS-173 did not enhance drug effects (Fig. 3). Collectively, our data may suggest why greater improvements in patient survival after PI3K and EGFR combination therapies have not yet been observed in HNSCC and other cancers clinically and support the need for additional detailed studies of PI3K and EGFR combination therapies using irreversible ERBB inhibitors.

Of the published HNSCC studies evaluating PI3K and EGFR ditherapies, most have been performed with either cetuximab
(Rebucci et al., 2011; D’Amato et al., 2014; Lattanzio et al., 2015) or the reversible EGFR inhibitors (e.g., gefitinib, erlotinib) (Young et al., 2013; Anisuzzaman et al., 2017). One exception is a recent report from Silva-Oliveira et al. (2017) that examined the responses to PI3K pathway inhibitors (including AKT inhibitor MK-2206) with two different irreversible EGFR inhibitors. In this study, pharmacologic inhibition or siRNA knockdown of AKT resulted in improved sensitivity to afatinib and allitinib (a second irreversible EGFR inhibitor) in HN13 cells (Silva-Oliveira et al., 2017). The need to suppress AKT phosphorylation in responses to PI3K + EGFR drug combinations is supported by studies of both EGFR-targeting antibodies (Benavente et al., 2009; Rebucci et al., 2011) and reversible inhibitors (Benavente et al., 2009; Rebucci et al., 2011; Young et al., 2013; Silva-Oliveira et al., 2017). In lung-cancer models, irreversible EGFR inhibitors have sustained reductions in EGFR phosphorylation and an improved ability to decrease effector AKT phosphorylation compared with reversible inhibitors (Kwak et al., 2005). The inability of reversible EGFR inhibitors to sustain suppression of EGFR...
and AKT phosphorylation has been linked to altered receptor trafficking (Wiley, 2003), a mechanism that does not affect the activity of irreversible inhibitors. In contrast, we did not observe greater reductions in AKT phosphorylation with HS-173 and afatinib than with gefitinib dual therapy (Fig. 5C). These data suggest that factors other than or in addition to the level of suppression of downstream EGFR-effector signaling may be responsible for mediating combination benefit and/or that specific inhibitor combinations may be required to achieve synergistic cell-death responses.

Of the emerging novel classes of PI3K and EGFR inhibitors that we evaluated, several are already in advanced clinical development for HNSCC and other cancers as monotherapy and combination therapies. For example, BKM120 improved survival when administered with paclitaxel (vs. paclitaxel and placebo) in a phase 2 HNSCC trial (Soulères et al., 2017), and BYL719 monotherapy demonstrated safety in patients with solid tumors (Juric et al., 2018). Of the irreversible EGFR inhibitors that we evaluated, dacomitinib has shown efficacy beyond that of cetuximab in preclinical models (Ather et al., 2013) and is undergoing evaluation in phase 2 studies in recurrent and metastatic HNSCC patients (NCT010768664, NCT01449201). Afatinib, although still indicated only for use in lung cancer patients, has also demonstrated similar efficacy to cetuximab (Seiwert et al., 2014) in HNSCC patients; this result is quite promising given that cetuximab was approved for use in HNSCC with radiation or cytotoxic chemotherapy after successful phase 3 trials (Bonner et al., 2006; Vermeulen et al., 2008). Afatinib is currently undergoing evaluation in a variety of treatment paradigms in HNSCC (including NCT01824823, NCT01427478, NCT02979977, and NCT01783587) and has also been tested in other solid tumor types as part of a combination therapy with inhibitors targeting PLK1 (NCT01206816), Src (NCT01999985), insulin-like growth factor receptor (NCT02191891), MEK (NCT02450656), or multiple receptor tyrosine kinases (NCT00988296) but not yet with PI3K inhibitors.

Many irreversible EGFR inhibitors have activity against both wild-type and mutated forms of EGFR (including those with T790M and/or C797S resistance mutations), which may contribute to their improved clinical efficacy over reversible drugs like gefitinib and erlotinib. Thus, the use of irreversible EGFR inhibitors with PI3K inhibitors in HNSCC may lead to more durable responses than reversible EGFR inhibitor combinations by eliminating not only EGFR mutations but also activation of compensatory signaling through PI3K as critical resistance mechanisms. Nevertheless, these combinations are still limited by other forms of resistance, including novel resistance mutations and co-dependent pathways, which will likely develop after prolonged exposure to even irreversible EGFR and PI3K inhibitor cotreatments.

Collectively, our work motivates the translation of specific PI3K and irreversible EGFR dual therapies into xenograft mouse models and other more clinically relevant systems. If such studies confirm our in vitro findings, clinical trials that evaluate these drug combinations will be warranted. More broadly, our data also motivate a need to develop additional biomarkers that can be used to determine not only whether a drug inhibits its target but also whether the drug inhibits pivotal downstream effector pathways capable of rescuing cell survival. Indeed, our findings suggest that responses may be mediated by complex downstream signaling networks or other yet-unidentified factors. Developing the next generation of adaptive biomarkers and rationally designed matched combination therapies may therefore be one key to improved survival for HNSCC patients.

### Authorship Contributions

**Participated in research design:** Michmerhuizen, Carey, Brenner

**Conducted experiments:** Michmerhuizen, Leonard, Matovina, Harris, Herbst

**Performed data analysis:** Michmerhuizen, Kulkarni, Zhai, Jiang

Wrote or contributed to the writing of the manuscript: Michmerhuizen, Brenner

### References


### Table 1

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Target</th>
<th>Reversible/ Irreversible</th>
<th>HSC-2 Synergy</th>
<th>Detroit 562 Synergy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gefitinib</td>
<td>EGFR</td>
<td>Reversible</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>EGFR</td>
<td>Reversible</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>BMS-398666</td>
<td>EGFR/ERBB2</td>
<td>Reversible</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>CP-724714</td>
<td>ERBB2</td>
<td>Reversible</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Afatinib</td>
<td>EGFR/ERBB2</td>
<td>Irreversible</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>TAK-285</td>
<td>EGFR/ERBB2</td>
<td>Irreversible</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>CUDC-101</td>
<td>EGFR/ERBB2/HDAC</td>
<td>Irreversible</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Dacomitinib</td>
<td>EGFR/ERBB2/ERBB4</td>
<td>Irreversible</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Michmerhuizen et al.


Michmerhuizen et al.

536

Address correspondence to: Dr. J. Chad Brenner, E-mail: chadbren@umich.edu